By Brazil Stock Guide – Dasa (DASA3) closed 2025 with a much clearer strategic direction, shifting its center of gravity toward diagnostics while working to repair a stretched balance sheet. The company reduced covenant leverage to 2.5x, down from 3.6x a year earlier, and generated R$460 million in operating cash flow in the fourth quarter. Recurring EBITDA reached R$397 million, up 21% year over year, signaling that underlying operations are improving even as headline numbers remain volatile. Dasa met its 2025 leverage target, ending the year at the upper end of its guided range.
The disconnect between operating performance and reported results remains the key issue. Dasa posted negative consolidated EBITDA of R$111 million in 4Q25, compared with positive R$403 million a year earlier, while net loss widened to R$948 million. The quarter was heavily impacted by non-recurring effects, including the sale of Hospital São Domingos and accounting adjustments tied to Rede Américas, its hospital joint venture with Amil. These items continue to obscure the company’s real operating trajectory.
“Throughout 2025, we repositioned the company with a focus on our core business and a consistent agenda of efficiency and cash generation. We ended the year as a more disciplined company with stronger execution capacity,” said Dasa CEO Rafael Lucchesi, in statement.
Diagnostics focus
Diagnostics is now clearly the core of the investment thesis. National diagnostics revenue rose 13% in the quarter to R$2.0 billion, driven by higher volumes, improved pricing mix and expansion in premium services, home care and B2B offerings. For the full year, revenue in the segment reached R$8.1 billion, up 10%.
Operational discipline is also improving. Dasa ended the year with 840 service units after closing underperforming locations, while maintaining a high level of customer satisfaction, with NPS at 76.3. Digitalization is beginning to play a more visible role: online scheduling reached 41% of total bookings, and the use of AI tools is helping improve efficiency and equipment utilization.
The strategy is increasingly about converting scale into margins rather than just expanding footprint — a shift that aligns Dasa more closely with global diagnostics peers.
Hospital exposure
Hospitals remain part of the story, though now with a more selective footprint. The company’s Northeast hospital and oncology operations posted strong growth, with revenue up nearly 15% to R$490 million and gross profit more than tripling. Gross margin expanded to 35.9%, reflecting better occupancy rates and a shift toward higher-complexity procedures.
The more relevant exposure, however, sits within Rede Américas. The joint venture reported EBITDA of R$169 million in the quarter, but this figure was impacted by a R$199 million non-cash accounting adjustment related to post-integration harmonization. Excluding these effects, EBITDA would have been R$368 million, with a 12.2% margin — reinforcing the view that underlying performance is stronger than reported.
Still, the lack of clean comparability continues to weigh on investor confidence, as the joint venture structure introduces additional layers of complexity to the financials.
Balance sheet reset
The balance sheet shows the most tangible progress. Dasa completed roughly R$1.9 billion in asset divestments in 2025, reducing net debt and improving financial flexibility. Net financial debt fell 46% year over year to R$5.4 billion, marking a meaningful shift for a company that had been under pressure for its leverage and capital allocation strategy.
The repositioning is becoming clearer. Dasa is moving away from a broad, capital-intensive healthcare model toward a more focused diagnostics platform, supported by a leaner balance sheet and selective hospital exposure through partnerships.